Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reached a new 52-week high on Monday . The company traded as high as $17.80 and last traded at $17.50, with a volume of 122,557 shares. The stock had previously closed at $17.43.

A number of research firms have weighed in on AMPH. BMO Capital Markets began coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, June 28th. They set a “market perform” rating and a $17.00 target price on the stock. TheStreet raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 14th. Finally, Needham & Company LLC decreased their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $16.80.

The firm has a 50 day moving average of $16.15 and a 200 day moving average of $13.29. The firm has a market cap of $784.79 million and a P/E ratio of 8750.00.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Monday, May 9th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.15. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The business had revenue of $59.40 million for the quarter, compared to analysts’ expectations of $62 million. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Equities analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.13 EPS for the current year.

In other Amphastar Pharmaceuticals news, EVP Diane G. Gerst sold 21,244 shares of the stock in a transaction that occurred on Tuesday, April 19th. The shares were sold at an average price of $12.89, for a total value of $273,835.16. Following the sale, the executive vice president now directly owns 39,713 shares in the company, valued at approximately $511,900.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Jason B. Shandell sold 9,904 shares of the stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $16.43, for a total transaction of $162,722.72. Following the completion of the sale, the president now owns 216,610 shares in the company, valued at $3,558,902.30. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Amphastar Pharmaceuticals stock. Russell Frank Co boosted its stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 289.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 83,965 shares of the company’s stock after buying an additional 62,407 shares during the period. Russell Frank Co owned approximately 0.19% of Amphastar Pharmaceuticals worth $1,204,000 as of its most recent filing with the SEC.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.